Collegium Pharmaceutical
COLL
eBay
EBAY
Halozyme Therapeutics
HALO
SilverCrest Metals
SILV
Workday
WDAY
(Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 100.11%1.39K | 98.55%-17.52K | 15.10%-539K | 14.01%-4.15M | 8.44%-1.08M | 16.24%-1.23M | -2.04%-1.21M | 36.38%-634.86K | -147.09%-4.83M | -112.12%-1.18M |
Net income from continuing operations | 20.81%-1.27M | 59.72%-1.34M | -53.73%-2.19M | -64.76%-8.85M | -37.04%-2.5M | -13.87%-1.6M | -233.16%-3.33M | -24.59%-1.42M | -33.20%-5.37M | -462.68%-1.82M |
Operating gains losses | --0 | ---- | ---- | 75.68%-125K | ---- | ---- | ---- | ---- | -1,345.42%-513.91K | ---39.29K |
Depreciation and amortization | 14.45%191K | 21.19%181.51K | 872.19%183.01K | 792.61%529.17K | 1,574.05%193.69K | 1,342.36%166.88K | 728.75%149.77K | 4.17%18.83K | -27.13%59.28K | -35.97%11.57K |
Other non cash items | -64.58%214.64K | -88.68%124.86K | -112.09%-22.47K | 798.03%2.64M | 5,199.09%747.73K | -2.28%605.97K | 1,104.23%1.1M | 192.32%185.94K | -88.08%294.22K | -101.77%-14.66K |
Change In working capital | 307.63%866.61K | -11.45%661.94K | 158.35%1.46M | 363.29%146.41K | -2,382.98%-750.7K | -551.64%-417.39K | 885.59%747.51K | 323.66%566.99K | -105.35%-55.61K | -110.42%-30.23K |
-Change in receivables | 116.28%133.82K | -381.59%-1.23M | 4,110.88%1.06M | -1,539.53%-1.43M | -216.04%-380.84K | -596.01%-821.77K | 9.86%-255.5K | 279.27%25.24K | -290.57%-87.4K | 4,744.47%328.21K |
-Change in inventory | 121.50%176.86K | 148.55%58.36K | -6,771.17%-743.44K | -1,101.73%-844.21K | 4,330.53%87.57K | ---822.71K | -178.74%-120.22K | 105.05%11.14K | -726.84%-70.25K | 92.49%-2.07K |
-Change in prepaid assets | 13.86%39.3K | 108.27%12.41K | 149.82%26.91K | 72.75%-9.81K | 494.64%95.04K | -29.50%34.52K | -455.20%-150.14K | 114.58%10.77K | -283.81%-36.01K | --15.98K |
-Change in payables and accrued expense | 79.69%1.12M | 62.06%1.19M | -128.86%-143.09K | 849.86%1.31M | -45.58%-542.08K | 12,168.30%620.78K | 1,075.66%736.79K | 12.00%495.81K | -85.67%138.05K | -219.72%-372.36K |
-Change in other working capital | -204.73%-598.83K | 16.96%627.58K | 5,151.51%1.26M | --1.12M | ---10.39K | --571.81K | --536.57K | --24.02K | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 100.11%1.39K | 98.55%-17.52K | 15.10%-539K | 13.80%-4.16M | 7.58%-1.09M | 16.24%-1.23M | -2.04%-1.21M | 36.38%-634.86K | -147.09%-4.83M | -112.12%-1.18M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 80.99%-18.24K | 95.84%-56.34K | -52K | -3,305.46%-1.52M | -2,258.47%-70.71K | -16,387.29%-95.96K | -8,309.30%-1.36M | 0 | -278.80%-44.7K | -3K |
Net PPE purchase and sale | 27.28%-15.24K | ---- | ---- | -371.69%-92.92K | --0 | -3,500.69%-20.96K | ---- | ---- | ---19.7K | ---3K |
Net business purchase and sale | --0 | ---- | ---- | -4,989.28%-1.27M | --11.29K | --0 | ---- | ---- | ---25K | --0 |
Net other investing changes | ---3K | ---4.5K | ---52K | ---157K | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 80.99%-18.24K | 95.84%-56.34K | ---52K | -3,305.46%-1.52M | -2,258.47%-70.71K | -16,387.29%-95.96K | -8,309.30%-1.36M | --0 | -278.80%-44.7K | ---3K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -75.72%4.17K | -99.43%27.74K | -7.04%523.78K | 24.45%6.06M | 26.51%643.81K | -98.84%17.17K | 1,227.06%4.84M | -77.61%563.46K | 141.21%4.87M | -28.58%508.88K |
Net issuance payments of debt | 61.56%-74.36K | -106.11%-211.97K | 2,953.39%152.74K | 141.19%3.37M | 1,157.31%102.7K | -112.98%-193.47K | 1,196.48%3.47M | -102.29%-5.35K | 254.55%1.4M | 97.15%-9.71K |
Net common stock issuance | --0 | --85.71K | -92.37%38.08K | 41.84%767.23K | -71.16%155.99K | --111.97K | --0 | --499.27K | -33.43%540.9K | -9.27%540.9K |
Net preferred stock issuance | --100.84K | -91.57%125.44K | --357.5K | -33.70%1.83M | --342K | --0 | 197.60%1.49M | --0 | 576.47%2.76M | --0 |
Net other financing activities | -122.61%-22.31K | 123.62%28.57K | -135.30%-24.54K | -46.90%90.41K | 293.32%43.12K | 1,035.89%98.66K | -166.91%-120.91K | 210.53%69.54K | -57.84%170.26K | -145.72%-22.31K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -75.72%4.17K | -99.43%27.74K | -7.04%523.78K | 24.45%6.06M | 26.51%643.81K | -98.84%17.17K | 1,227.06%4.84M | -77.61%563.46K | 141.21%4.87M | -28.58%508.88K |
Net cash flow | ||||||||||
Beginning cash position | -81.14%450.91K | 313.89%497.02K | 194.67%564.24K | -3.52%191.49K | 24.96%1.08M | 179.72%2.39M | -92.90%120.09K | -3.52%191.49K | 80.22%198.47K | 1,943.90%865.82K |
Current changes in cash | 99.03%-12.69K | -102.03%-46.12K | 5.85%-67.22K | 5,434.24%372.76K | 23.23%-517.68K | -11,756.48%-1.31M | 371.22%2.27M | -104.78%-71.4K | -107.91%-6.99K | -531.95%-674.33K |
End cash Position | -59.50%438.22K | -81.14%450.91K | 313.89%497.02K | 194.67%564.24K | 194.67%564.24K | 24.96%1.08M | 179.72%2.39M | -92.90%120.09K | -3.52%191.49K | -3.52%191.49K |
Free cash flow | 98.89%-13.85K | 94.59%-69.36K | 15.10%-539K | 12.23%-4.26M | 7.81%-1.09M | 14.84%-1.25M | -6.66%-1.28M | 36.38%-634.86K | -148.10%-4.85M | -112.65%-1.18M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |